Alzheimer’s disease (AD), today is the most prevalent form of dementia afflicting more than 50 million people worldwide (Queiroz et al., 2022, Varesi et al., 2022), and with a doubling time of 20 years could easily...read more
Latest news and features
Velsera Is Building an Ecosystem that Accelerates the R&D Loop and Democratizes Omics Data to Propel the Next Era of Precision Medicine
My most recent interview is with Gavin Nichols, the CEO of the newly formed company Velsera. Velsera launched in January 2023, after quietly acquiring the three companies Seven Bridges, UgenTec, and Pierian in mid...read more
The Cheap Genome Is Not Enough – We Need an “Accurate and Good Genome”
We may still be five Years out until We Can Sequence Everyone I had the chance to attend the Precision Medicine World Conference PMWC 2023 SV in the last couple of days. Some 2,000+ individuals from across the life...read more
ONTOFORCE Wants to Increase Data Literacy and Empower Citizen Data Scientists
This month’s “Company Spotlight” provides a closer look at ONTOFORCE, the creator of a semantic search technology platform for insight generation. I spoke with Valerie Morel, CEO of ONTOFORCE, about ONTOFORCE’s platform...read more
Time Is What We Want Most – Why Wasting Any More of It?
As many of us continuously experience, combing through the latest news in any scientific research area or a given commercial sector – whether it is to stay up-to-date in a specific field, view the latest trends in...read more
Omicron NTD Insertions: A new Route for Variant Generation?
My most recent article published was a quick review of what was known about the SARS Omicron variant in the post 2021, The Year of the Various SARS-CoV-2 Variants of Concern – from Alpha to Omicron. While researching...read more
We Invite you to join enlightenbio’s Subject Matter Expert Network!
enlightenbio is a boutique consultancy providing product strategy and market intelligence to precision medicine industries. Our mission is to help our clients successfully develop, launch, and market exceptional...read more
Enlightenbio Releases New Report – Database of Biomarkers Curated from US Oncology Trials
Palo Alto, CA, January 21, 2022 – The “Database of Biomarkers Curated from Oncology Trials” report has been added to the enlightenbio LLC product offering. This new report provides insights into...read more
2021, The Year of the Various SARS-CoV-2 Variants of Concern – from Alpha to Omicron
A review of the various SARS-CoV-2 Omicron mutations 2021 was the year of multiple variants of concerns (VOCs) starting with the Alpha variant in the UK, which was first detected in November 2020, and spread quickly by...read more
Patient-Centric Rare Disease Genome Maps Join The Web
For far too long, rare disease patients and their guardians have had to wait “forever” for genetic information to be returned back to them. All of that is about to change: thanks to the convergence of mapping...read more
